What is Versavo?

Versavo is a biosimilar bevacizumab and is indicated for the treatment of multiple cancers. It is used in combination with other chemotherapy drugs to treat cervical, colorectal, glioblastoma and non-squamous non-small cell lung cancer.

Storage Conditions

2-8 degrees Celsius (refrigerate),Do not freeze.

Presentation

Vial containing concentrate for solution for infusion.

Route of Administration

Intravenous (IV) (upon prescription only and administered by a healthcare provider.)

Indications

Metastatic Colorectal Cancer (mCRC):

mCRC is a stage of colorectal cancer where it spreads beyond the colon or rectum to other parts of the body, often requiring aggressive treatment for better survival.

How Bevacizumab works?

Mechanism of Action

Bevacizumab binds to vascular endothelial growth factor (VEGF), the key driver of vasculogenesis and angiogenesis, and thereby inhibits the binding of VEGF to its receptors, Flt-1 (VEGFR-1) and KDR (VEGFR-2), on the surface of endothelial cells. Neutralising the biological activity of VEGF regresses the vascularisation of tumours, normalises remaining tumour vasculature, and inhibits the formation of new tumour vasculature, thereby inhibiting tumour growth.

We Meet Global Standards

CDSCO
ISO 9001
INVIMA
SAHPRA

Our News, Stories, and Insights

Aurigene
  • News
  • 12-06-2024

Aurigene Pharma announces opening of biologics facility in Genome Valley

  • News
  • 22-05-2024

Dr Reddy's inks licencing agreement with Alvotech

  • News
  • 21-05-2024

Alvotech and Dr. Reddy’s enter into collaboration for its biosimilar to treat osteoporosis

  • News
  • 21-05-2024

Dr. Reddy's Secures Rights For Denosumab In US, Europe And UK